drugset / Trial / NCT06727058
Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older
RandomizedSequentialTriple-blindPrevention
Summary
The purpose of this study is to evaluate a pandemic flu H5 strain messenger ribonucleic acid (mRNA) vaccine at 3 dose levels (low, medium, and high) in comparison with placebo in 276 healthy adult participants to select the adequate dose for further clinical development. The duration per participant will be approximately 13 months.
Timeline
- Start
- 2024-12-09
- Primary completion
- 2026-03-24
- Completion
- 2026-03-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pandemic flu H5 mRNA vaccine | Messenger RNA (mRNA) | — | Intramuscular |
Indications
No indication recorded.